Neovascular age-related macular degeneration (nvamd)

Clinical trials for Neovascular age-related macular degeneration (nvamd) explained in plain language.

Never miss a new study

Get alerted when new Neovascular age-related macular degeneration (nvamd) trials appear

Sign up with your email to follow new studies for Neovascular age-related macular degeneration (nvamd), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Completed 2

New eye drug EYE103 aims to restore vision in macular degeneration and vein occlusion

Disease control Recruiting now

This Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…

Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)

Phase 2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control

Last updated Sep 06, 2026 00:00 UTC

Neovascular age-related macular degeneration (nvamd)

Get alerted when new Neovascular age-related macular degeneration (nvamd) trials appear

New eye drug EYE103 aims to restore vision in macular degeneration and vein occlusion